W. L. GORE & ASSOCIATES ANNOUNCES SUMMARY OF GORE PROPATEN VASCULAR GRAFT STUDY DATA PRESENTED AT 34TH ANNUAL VEITHSYMPOSIUM™

Multi-year, multi-site data adds to the growing body of evidence for the GORE PROPATEN Vascular Graft
W. L. Gore & Associates (Gore) announced that interim results from multi-year, multi-center studies using the GORE PROPATEN Vascular Graft were presented recently at the 34th Annual VEITHsymposium™ in New York. The GORE PROPATEN Device is the first device with an ePTFE-heparin combination that is designed to reduce thrombosis (clotting), a common cause of graft failure. The average one-year primary patency from all the reported literature on the GORE PROPATEN Vascular Graft in below-knee bypasses has been reported to be 80 percent.
On the one-year anniversary of the commercial launch of the GORE PROPATEN Vascular Graft in the United States, several presentations at this year’s VEITHsymposium add to the growing body of evidence for the use of this graft in lower-limb and dialysis access applications.

full press release >> http://www.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20071211005789&newsLang=en